Bookmark and Share
BioAssay: AID 686988

Counterscreen for agonists of the human trace amine associated receptor 1 (TAAR1): Fluorescence-based cell-based high throughput dose response assay to identify nonselective Ga16 antagonists

Name: Counterscreen for agonists of the human trace amine associated receptor 1 (TAAR1): Fluorescence-based cell-based high throughput dose response assay to identify nonselective Ga16 antagonists. ..more
_
   
 Tested Compounds
 Tested Compounds
All(414)
 
 
Active(2)
 
 
Inactive(412)
 
 
 Tested Substances
 Tested Substances
All(415)
 
 
Active(2)
 
 
Inactive(413)
 
 
AID: 686988
Data Source: The Scripps Research Institute Molecular Screening Center (CHO-GA16_ANT_FLUO8_1536_3XIC50 DCSRUN for TAAR1 AG)
BioAssay Type: Confirmatory, Concentration-Response Relationship Observed
Depositor Category: NIH Molecular Libraries Probe Production Network
Deposit Date: 2013-05-21

Data Table ( Complete ):           View Active Data    View All Data
Target
BioActive Compounds: 2
Related Experiments
Show more
AIDNameTypeComment
624467Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1)Screeningdepositor-specified cross reference: Primary screen (TAAR1 activators in singlicate)
624477Summary of the probe development effort to identify agonists of the human trace amine associated receptor 1 (TAAR1)Summarydepositor-specified cross reference: Summary (TAAR1 activators)
651783Fluorescence-based cell-based primary high throughput confirmation assay to identify agonists of the human trace amine associated receptor 1 (TAAR1)Screeningdepositor-specified cross reference: Confirmation screen (TAAR1 agonists in triplicate)
651787Counterscreen for agonists of the human trace amine associated receptor 1 (hTAAR1): Fluorescence-based cell-based high throughput screening assay to identify nonselective agonistsScreeningdepositor-specified cross reference: Counterscreen (nonselective Ga16 agonists in triplicate)
651951Counterscreen for agonists of the human trace amine associated receptor 1 (hTAAR1): Fluorescence-based cell-based high throughput screening assay to identify hTAAR1 agonists that also desensitize TAAR1 receptor response.Screeningdepositor-specified cross reference: Counterscreen (TAAR1 agonists that respond because they are TAAR1 antagonists in triplicate)
651952Counterscreen for agonists of the human trace amine associated receptor 1 (hTAAR1): Fluorescence-based cell-based high throughput screening assay to identify nonselective Ga16 antagonistsScreeningdepositor-specified cross reference: Counterscreen(nonselective Ga16 antagonists that may be caused by an agonist response in a dual scre
743229Fluorescence-based cell-based late stage dose response assay to identify agonists of the human trace amine associated receptor 1 (TAAR1)Confirmatorydepositor-specified cross reference
743231Counterscreen for agonists of the human trace amine associated receptor 1 (hTAAR1): Fluorescence-based cell-based late stage dose response assay to identify hTAAR1 agonist that also desensitize TAAR1 receptor response.Confirmatorydepositor-specified cross reference
743232Counterscreen for agonists of the human trace amine associated receptor 1 (TAAR1): Fluorescence-based cell-based late stage dose response assay to identify nonselective Ga16 agonistsConfirmatorydepositor-specified cross reference
743233Counterscreen for agonists of the human trace amine associated receptor 1 (TAAR1): Fluorescence-based cell-based late stage dose response assay to identify nonselective Ga16 antagonistsConfirmatorydepositor-specified cross reference
743490On Hold
743491On Hold
743494On Hold
743496On Hold
1053177On Hold
1053178On Hold
1053179On Hold
1053181On Hold
686983Counterscreen for agonists of the human trace amine associated receptor 1 (TAAR1): Fluorescence-based cell-based high throughput dose response assay to identify nonselective Ga16 agonistsConfirmatorysame project related to Summary assay
686984Counterscreen for agonists of the human trace amine associated receptor 1 (hTAAR1): Fluorescence-based cell-based high throughput dose response assay to identify hTAAR1 agonist that also desensitize TAAR1 receptor response.Confirmatorysame project related to Summary assay
686985Fluorescence-based cell-based high throughput dose response assay to identify agonists of the human trace amine associated receptor 1 (TAAR1)Confirmatorysame project related to Summary assay
Description:
Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)
Affiliation: RTI International
Assay Provider: Brian P. Gilmour, RTI International
Network: Molecular Library Probe Production Centers Network (MLPCN)
Grant Proposal Number: 1R21NS064780-01A1
Grant Proposal PI: Brian P. Gilmour, RTI International
External Assay ID: CHO-GA16_ANT_FLUO8_1536_3XIC50 DCSRUN for TAAR1 AG

Name: Counterscreen for agonists of the human trace amine associated receptor 1 (TAAR1): Fluorescence-based cell-based high throughput dose response assay to identify nonselective Ga16 antagonists.

Description:

Heterotrimeric G-protein coupled receptors (GPCRs) are major targets for disease therapeutics, due in part to their broad tissue distribution, structural diversity, varied modes of action, and disease-associated mutations (1-4). TAAR1 (trace amine associated receptor 1) is a G protein-coupled receptor activated by trace amines. Trace amines (TA) such as Beta-phenethylamine (Beta-PEA), p-tyramine (TYR), octopamine, and tryptamine are endogenous amine compounds that account for less than 1% of the biogenic amines in most brain regions (5), and exert pharmacological actions in humans (6,7). In addition to binding Beta-PEA and TYR, rat TAAR1 is also activated by dopamine, octopamine, tryptamine, amphetamine, and lysergic acid (8-10). TAs are of particular interest because they have been shown to modulate the activity of neurotransmitters such as dopamine (11-13) and gamma-amino butyric acid (14-16) and alterations in their brain levels are associated with schizophrenia (17-19) and depression (20, 21). Their potential to modulate dopaminergic activity suggests that they may play a role in the efficacy of L-DOPA in treating Parkinson disease4 and addiction (13). In humans, only TAAR1 has been shown to be activated by Beta-PEA and TYR, resulting in increased cyclic adenosine monophosphate (cAMP) accumulation through coupling to Gs (9, 10). Endogenous hTAAR1 activity is predominantly coupled to G-alpha-s and the accumulation of cAMP. The variety of compounds potentially acting at this receptor makes it attractive to assume that hTAAR1 is involved in a variety of integrated CNS processes such as mood and cognition. As a result, hTAAR1 is an interesting target for the development of ligands to probe the role of this receptor in CNS function and disease. For this project, the assay provider has created a cell line expressing the hTAAR1 in a parent cell line (RD-HGA16 cells, Molecular Devices) that stably over expresses the promiscuous G-protein, G-alpha-16, thereby coupling hTAAR1 activation to mobilization of internal calcium stores. Because TAs may be involved in modulating a variety of behaviors including mood, cognition, and addiction, it is of interest to discover novel ligands for TAAR1 to probe the role TAs play in brain function (22).

References:

1. Pan, H.L., Wu, Z.Z., Zhou, H.Y., Chen, S.R., Zhang, H.M., and Li, D.P., Modulation of pain transmission by G-protein-coupled receptors. Pharmacol Ther, 2008. 117(1): p. 141-61.
2. Lagerstrom, M.C. and Schioth, H.B., Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat Rev Drug Discov, 2008. 7(4): p. 339-57.
3. Thompson, M.D., Cole, D.E., and Jose, P.A., Pharmacogenomics of G protein-coupled receptor signaling: insights from health and disease. Methods Mol Biol, 2008. 448: p. 77-107.
4. Bosier, B. and Hermans, E., Versatility of GPCR recognition by drugs: from biological implications to therapeutic relevance. Trends Pharmacol Sci, 2007. 28(8): p. 438-46.
5. Bunzow JR, Sonders MS, Arttamangkul S, Harrison LM, Zhang G, Quigley DI, Darland T, Suchland KL, Pasumamula S, Kennedy JL, Olson SB, Magenis RE, Amara SG, Grandy DK. Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol. 2001 Dec;60(6):1181-8.
6. Premont RT, Gainetdinov RR, Caron MG: Following the trace of elusive amines. Proc Natl Acad Sci U S A 2001;98:9474-9475.
7. Branchek TA, Blackburn TP: Trace amine receptors as targets for novel therapeutics: legend, myth and fact. Curr Opin Pharmacol 2003;3:90-97.
8. Borowsky B, Adham N, Jones KA, Raddatz R, Artymyshyn R, Ogozalek KL, et al: Trace amines: identification of a family of mammalian G protein-coupled receptors. Proc Natl Acad Sci U S A 2001;98:8966-8971.
9. Bunzow JR, Sonders MS, Arttamangkul S, Harrison LM, Zhang G, Quigley DI, et al: Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol 2001;60:1181-1188.
10. Lindemann L, Ebeling M, Kratochwil NA, Bunzow JR, Grandy DK, Hoener MC: Trace amine-associated receptors form structurally and functionally distinct subfamilies of novel G protein-coupled receptors. Genomics 2005;85:372-385.
11. Jones RS: Specific enhancement of neuronal responses to catecholamine by p-tyramine. J Neurosci Res 1981;6:49-61.
12. Mercuri NB, Bernardi G: The "magic" of L-dopa: why is it the gold standard Parkinson's disease therapy? Trends Pharmacol Sci 2005;26:341-344.
13. Miller GM, Verrico CD, Jassen A, Konar M, Yang H, Panas H, et al: Primate trace amine receptor 1 modulation by the dopamine transporter. J Pharmacol Exp Ther 2005;313:983-994.
14. Dourish CT, Cooper SJ: Pharmacology of beta-phenylethylamine induced seizures in mice. Prog Neuropsychopharmacol Biol Psychiatry 1983;7:787-790.
15. Berretta N, Giustizieri M, Bernardi G, Mercuri NB: Trace amines reduce GABA(B) receptor-mediated presynaptic inhibition at GABAergic synapses of the rat substantia nigra pars compacta. Brain Res 2005;1062:175-178.
16. Federici M, Geracitano R, Tozzi A, Longone P, Di Angelantonio S, Bengtson CP, et al: Trace amines depress GABA B response in dopaminergic neurons by inhibiting G-betagamma-gated inwardly rectifying potassium channels. Mol Pharmacol 2005;67:1283-1290.
17. Boulton AA: Some aspects of basic psychopharmacology: the trace amines. Prog Neuropsychopharmacol Biol Psychiatry 1982;6:563-570.
18. Anderson GM, Gerner RH, Cohen DJ, Fairbanks L: Central tryptamine turnover in depression, schizophrenia, and anorexia: measurement of indoleacetic acid in cerebrospinal fluid. Biol Psychiatry 1984;19: 1427-1435.
19. Duan J, Martinez M, Sanders AR, Hou C, Saitou N, Kitano T, et al: Polymorphisms in the trace amine receptor 4 (TRAR4) gene on chromosome 6q23.2 are associated with susceptibility to schizophrenia. Am J Hum Genet 2004;75:624-638.
20. Davis BA, Boulton AA: The trace amines and their acidic metabolites in depression-an overview. Prog Neuropsychopharmacol Biol Psychiatry 1994;18:17-45.
21. Baker GB, Coutts RT, Greenshaw AJ: Neurochemical and metabolic aspects of antidepressants: an overview. J Psychiatry Neurosci 2000; 25:481-496.
22. Navarro HA, Gilmour BP, Lewin AH. A rapid functional assay for the human trace amine-associated receptor 1 based on the mobilization of internal calcium. J Biomol Screen. 2006 Sep;11(6):688-93. Epub 2006 Jul 10.

Keywords:

DCSRUN, Dose Response, Counterscreen, mood, cognition, addiction, AG, ACT, FLIPR, TAAR1, hTAAR1, MGC126874, MGC138399, RP11-295F4.9, TA1, TAR1, TRAR1, receptor, taR-1, trace amine receptor 1, trace amine-associated receptor 1, GPCR, Fluo-8, FLUO8, RD-HGA, RD-HGA16, cells, cell-based, CHO, dye, calcium, kinetic, fluorescence, agonist, agonism, activator, activate, increase, HTS, high throughput screen, 1536, Scripps Florida, The Scripps Research Institute Molecular Screening Center, SRIMSC, Molecular Libraries Probe Production Centers Network, MLPCN.
Protocol
Assay Overview:
The purpose of this assay is to determine whether compounds identified in a previous set of experiments entitled, "Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1)" (AID 624467) also behave as non-specific antagonists. In this assay the CHO-Ga16 cell line is incubated with a fluorescent, cell permeable calcium indicator dye (Fluo-8). The dye serves to monitor levels of intracellular calcium. Test compounds are then added to the cells, followed by the addition of ATP, a purinergic receptor agonist. As designed, compounds that decrease calcium mobilization will cause a decrease in the relative fluorescence of the indicator dye, leading to decreased well fluorescence. The compounds are tested at 29.9uM with a 10 point, 1:3 dilution series in triplicate.
Protocol Summary:
The CHO-HGA16 cell line was routinely cultured in T-175 sq cm flasks at 37 C and 95% relative humidity (RH). The growth media consisted of Ham's F-12 Nutrient Media (F-12) supplemented with 10% v/v heat-inactivated qualified fetal bovine serum, 20 mM HEPES, 200 ug/mL Hygromycin and 1X antibiotic mix (penicillin and streptomycin).
The day before the assay 750 cells in 3 uL of growth media, lacking Hygromycin, were seeded into each well of 1536 well microtiter plates and allowed to incubate at 37 C, 5% CO2, and 95 % RH for 17-24 hours. Next, 2 uL of the fluorogenic Fluo-8 intracellular calcium indicator mixture (prepared according to the manufacturer's protocol) was added to each well. Plates were then incubated for 75 minutes at 37 C, 5% CO2, and 95 % RH, followed by 30 minute incubation at room temperature. Then, 30nL of 100% DMSO was added to each well and incubated at room temperature for 5 minutes. Then, 15 nL of test compound in DMSO were dispensed to appropriate wells. The assay was started by performing a basal read of plate fluorescence (470-495 nm excitation and 515-575 nm emission) for 5 seconds on the FLIPR Tetra (Molecular Devices). Then a real time fluorescence measurement was immediately performed for the remaining 140 seconds of the assay. Then, a basal read of plate fluorescence for 5 seconds on the FLIPR Tetra prior to all wells being treated with EC80 of ATP in DMSO. Then a real time fluorescence measurement was immediately performed for the remaining 140 seconds of the assay (this is the read for the antagonist mode).
Hits for this assay were determined according to the following mathematical expression:
Ratio = I_Max / I_Min
Where:
I_Max represents the maximum measured fluorescence emission intensity over the 140 second read for the antagonist mode and;
I_Min represents the minimum (basal) measured fluorescence emission intensity before EC80 of ATP was added.
The percent inhibition was calculated from the median ratio as follows:
%_Inhibition = ( 1 - ( Ratio Test_Compound - Median_Ratio_High_Control ) / ( Median_Ratio_Low_Control - Median_Ratio_High_Control ) ) ) * 100
Where:
Test_Compound is defined as wells containing test compound.
High_Control is defined as wells containing DMSO.
Low_Control is defined as wells containing ATP (EC80) and DMSO.
For each test compound, percent inhibition was plotted against compound concentration. A four parameter equation describing a sigmoidal dose-response curve was then fitted with adjustable baseline using Assay Explorer software (Accelrys Inc). The reported IC50 values were generated from fitted curves by solving for the X-intercept value at the 50% activation level of the Y-intercept value. In cases where the highest concentration tested (i.e. 29.9 uM) did not result in greater than 50% activation, the IC50 was determined manually as greater than 29.9 uM.
PubChem Activity Outcome and Score:
Compounds with an IC50 greater than 10 uM were considered inactive. Compounds with an IC50 equal to or less than 10 uM were considered active.
The PubChem Activity Score range for active compounds is 100-100, and for inactive compounds 91-0.
List of Reagents:
RD-HGA Cell Line (Molecular Devices)
Agonist:ATP (Sigma, A9187)
Calcium sensitive dye: Fluo-8 No Wash Calcium Assay Kit; (AAT Bioquest, part 36316)
Growth media: Ham's F-12; 10% FBS, 20 mM HEPES, 200ug/ml Hygromycin
Assay media: Ham's F-12, 10% FBS, 20 mM HEPES
Assay plates: Corning black/clear 1536 well FLIPR plate; (Corning, part 7338)
Probenecid: 250 mM (pH 8.0); (Sigma P8761)
Ham's F-12 Nutrient Mixture (Invitrogen, part 11765-054)
Charcoal/Dextran-treated Feta Bovine Serum (Hyclone, part SH3006803HI)
Penicillin-Streptomycin (100X) (Invitrogen, 15070-063)
Hygromycin B (Invitrogen, part 10687-010)
Detachin Cell Detachment Reagent (Genlantis, part T100100)
T-175 Flasks (Nunc, part 159910)
Comment
Due to the increasing size of the MLPCN compound library, this assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, and compounds that modulate well fluorescence. All test compound concentrations reported above and below are nominal; the specific test concentration(s) for a particular compound may vary based upon the actual sample provided by the MLSMR. Not all compounds requested were available from the MLSMR. Due to limitations in the amount of MLSMR compounds that could be selected for retesting, compounds that demonstrated selective activity in AID 624467 vs. other Fluo8 agonist screening assays run at the SRIMSC were prioritized for testing in this assay.
Categorized Comment - additional comments and annotations
From BioAssay Depositor:
Assay: CurveFit [1]: Equation: =( ( [Maximal Response] * [Concentration]^[Hill Slope] ) / ( [Inflection Point Concentration]^[Hill Slope] + [Concentration]^[Hill Slope] ) ) + [Baseline Response]
Assay: CurveFit [1]: Mask: Excluded Points
Assay: Dictionary: Version: 0.1
From PubChem:
Assay Format: Cell-based
Assay Cell Type: CHO
From ChEMBL:
Assay Format: Cell-based
Assay Type: Functional
Result Definitions
Show more
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
ScoreThe BioAssay activity ranking scoreInteger
1QualifierActivity Qualifier identifies if the resultant data IC50 came from a fitted curve or was determined manually to be less than or greater than its listed IC50 concentration.String
2IC50*The concentration at which 50 percent of the activity in the inhibitor assay is observed; (IC50) shown in micromolar.FloatμM
3LogIC50Log10 of the qualified IC50 (IC50) from the inhibitor assay in M concentrationFloat
4Maximal ResponseThe maximal or asymptotic response above the baseline as concentration increases without bound.Float
5Baseline ResponseAdjustable baseline of the curve fit, minimal response value.Float
6Inflection Point ConcentrationThe concentration value for the inflection point of the curve.FloatμM
7Hill SlopeThe variable HillSlope describes the steepness of the curve. This variable is called the Hill slope, the slope factor, or the Hill coefficient. If it is positive, the curve increases as X increases. If it is negative, the curve decreases as X increases. A standard sigmoid dose-response curve (previous equation) has a Hill Slope of 1.0. When HillSlope is less than 1.0, the curve is more shallow. When HillSlope is greater than 1.0, the curve is steeper. The Hill slope has no units.Float
8Response RangeThe range of Y.Float
9Chi SquareA measure for the 'goodness' of a fit. The chi-square test (Snedecor and Cochran, 1989) is used to test if a sample of data came from a population with a specific distribution.Float
10RsquareThis statistic measures how successful the fit explains the variation of the data; R-square is the square of the correlation between the response values and the predicted response values.Float
11Number of DataPointsOverall number of data points of normalized percent inhibition that was used for calculations (includes all concentration points); in some cases a data point can be excluded as outlier.Integer
12Excluded PointsFlags to indicate which of the dose-response points were excluded from analysis. (1) means the point was excluded and (0) means the point was not excluded.String
13Inhibition at 0.0015 uM [1] (0.0015μM**)Value of %inhibition at 0.0015 micromolar inhibitor concentration; replicate [1]Float%
14Inhibition at 0.0015 uM [2] (0.0015μM**)Value of %inhibition at 0.0015 micromolar inhibitor concentration; replicate [2]Float%
15Inhibition at 0.0015 uM [3] (0.0015μM**)Value of %inhibition at 0.0015 micromolar inhibitor concentration; replicate [3]Float%
16Inhibition at 0.0045 uM [1] (0.0045μM**)Value of %inhibition at 0.0045 micromolar inhibitor concentration; replicate [1]Float%
17Inhibition at 0.0045 uM [2] (0.0045μM**)Value of %inhibition at 0.0045 micromolar inhibitor concentration; replicate [2]Float%
18Inhibition at 0.0045 uM [3] (0.0045μM**)Value of %inhibition at 0.0045 micromolar inhibitor concentration; replicate [3]Float%
19Inhibition at 0.014 uM [1] (0.014μM**)Value of %inhibition at 0.014 micromolar inhibitor concentration; replicate [1]Float%
20Inhibition at 0.014 uM [2] (0.014μM**)Value of %inhibition at 0.014 micromolar inhibitor concentration; replicate [2]Float%
21Inhibition at 0.014 uM [3] (0.014μM**)Value of %inhibition at 0.014 micromolar inhibitor concentration; replicate [3]Float%
22Inhibition at 0.041 uM [2] (0.041μM**)Value of %inhibition at 0.041 micromolar inhibitor concentration; replicate [2]Float%
23Inhibition at 0.041 uM [3] (0.041μM**)Value of %inhibition at 0.041 micromolar inhibitor concentration; replicate [3]Float%
24Inhibition at 0.041 uM [1] (0.041μM**)Value of %inhibition at 0.041 micromolar inhibitor concentration; replicate [1]Float%
25Inhibition at 0.12 uM [3] (0.12μM**)Value of %inhibition at 0.12 micromolar inhibitor concentration; replicate [3]Float%
26Inhibition at 0.12 uM [1] (0.12μM**)Value of %inhibition at 0.12 micromolar inhibitor concentration; replicate [1]Float%
27Inhibition at 0.12 uM [2] (0.12μM**)Value of %inhibition at 0.12 micromolar inhibitor concentration; replicate [2]Float%
28Inhibition at 0.37 uM [3] (0.37μM**)Value of %inhibition at 0.37 micromolar inhibitor concentration; replicate [3]Float%
29Inhibition at 0.37 uM [1] (0.37μM**)Value of %inhibition at 0.37 micromolar inhibitor concentration; replicate [1]Float%
30Inhibition at 0.37 uM [2] (0.37μM**)Value of %inhibition at 0.37 micromolar inhibitor concentration; replicate [2]Float%
31Inhibition at 1.1 uM [3] (1.1μM**)Value of %inhibition at 1.1 micromolar inhibitor concentration; replicate [3]Float%
32Inhibition at 1.1 uM [2] (1.1μM**)Value of %inhibition at 1.1 micromolar inhibitor concentration; replicate [2]Float%
33Inhibition at 1.1 uM [1] (1.1μM**)Value of %inhibition at 1.1 micromolar inhibitor concentration; replicate [1]Float%
34Inhibition at 3.3 uM [2] (3.3μM**)Value of %inhibition at 3.3 micromolar inhibitor concentration; replicate [2]Float%
35Inhibition at 3.3 uM [3] (3.3μM**)Value of %inhibition at 3.3 micromolar inhibitor concentration; replicate [3]Float%
36Inhibition at 3.3 uM [1] (3.3μM**)Value of %inhibition at 3.3 micromolar inhibitor concentration; replicate [1]Float%
37Inhibition at 10 uM [3] (10μM**)Value of %inhibition at 10 micromolar inhibitor concentration; replicate [3]Float%
38Inhibition at 10 uM [1] (10μM**)Value of %inhibition at 10 micromolar inhibitor concentration; replicate [1]Float%
39Inhibition at 10 uM [2] (10μM**)Value of %inhibition at 10 micromolar inhibitor concentration; replicate [2]Float%
40Inhibition at 29.9 uM [1] (29.9μM**)Value of %inhibition at 29.9 micromolar inhibitor concentration; replicate [1]Float%
41Inhibition at 29.9 uM [2] (29.9μM**)Value of %inhibition at 29.9 micromolar inhibitor concentration; replicate [2]Float%
42Inhibition at 29.9 uM [3] (29.9μM**)Value of %inhibition at 29.9 micromolar inhibitor concentration; replicate [3]Float%

* Activity Concentration. ** Test Concentration.
Additional Information
Grant Number: 1R21NS064780-01A1

Data Table (Concise)
Data Table ( Complete ):     View Active Data    View All Data
Classification
PageFrom: